The differences between Ozempic and Wegovy — and why they matter for weight loss

Same drug, but the licence is not a technicality

The single most important thing to know: the MHRA licenses medicines for specific indications based on the clinical trials submitted for each. Novo Nordisk ran the STEP programme (a large series of trials) to generate the evidence needed to license semaglutide specifically for weight management, at higher doses, under the Wegovy brand. Ozempic was approved separately, on different evidence, for type 2 diabetes.

This is not a branding quirk. A UK prescriber offering Ozempic for weight loss would be prescribing it off-label, outside its licensed use, without the weight-loss evidence base underpinning it. The NHS and the MHRA are clear on this: the NHS semaglutide medicines page sets out both products and their distinct indications. Wegovy is the appropriate licensed route for weight management.

If you have come across Ozempic being marketed for weight loss online, treat that as a red flag rather than a shortcut. If you are wondering whether there is any real difference between Ozempic and Wegovy, the answer goes well beyond the name on the box. The availability of a name does not reflect its legal or clinical suitability for your goal.

How the doses differ between the two products

The dosing schedules are meaningfully different, and this reflects the different clinical objectives each product was designed for. Wegovy starts at 0.25 mg weekly and escalates (guided by your prescriber) through 0.5 mg, 1.0 mg, 1.7 mg, and up to 2.4 mg as the standard maintenance dose. A higher 7.2 mg dose was subsequently approved by the MHRA in early 2026, available initially via three 2.4 mg pens weekly and then via a dedicated single-dose pen approved in April 2026.

Ozempic's licensed doses for diabetes sit in a lower range. The weight-loss evidence that supports Wegovy comes from trials conducted at the 2.4 mg level, if a lower dose were used, you would not be receiving the dose on which the weight-loss data is based. For a closer look at what the difference between Ozempic and Wegovy actually means in practice, including how the doses and licensed uses compare, that page sets it out clearly. Someone obtaining Ozempic and hoping for Wegovy-level results is working from a false premise, not just a name mix-up.

Dose titration for either product is a clinical decision. Trying to self-manage the escalation schedule without prescriber oversight is unsafe. If you are curious about how Wegovy works and what the treatment involves, that page covers the licensed product in full detail.

Which patients each product is designed for

Wegovy's licensed eligibility in the UK is: adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber also considers your full health history, any contraindications, and your current medicines.

Ozempic is for adults with type 2 diabetes where blood-glucose management is the clinical objective, not weight loss as such, even though weight change may occur as a secondary effect. Someone without type 2 diabetes has no licensed clinical rationale for Ozempic.

People sometimes ask whether they can transfer between the two products. That is a conversation for a prescriber, not something to navigate independently. If you are already on a GLP-1 medicine and thinking about switching, our clinical team at our prescriber profile page gives a sense of how that clinical oversight works at nume. The Wegovy vs Ozempic comparison also covers this ground in more depth.

What is actually licensed and available for weight loss in the UK

Two injectable medicines are currently licensed for weight management in UK adults: Wegovy (semaglutide) and Mounjaro (tirzepatide). Mounjaro is a dual GIP and GLP-1 receptor agonist (it activates two appetite-related pathways rather than one) and is the only medicine of its kind licensed in the UK. Evidence from the SURMOUNT-1 trial, published in the New England Journal of Medicine, showed average body-weight reductions of around 20–21% at the highest dose over 72 weeks. The SURMOUNT-5 head-to-head trial, also published in the NEJM in 2025, found tirzepatide produced greater average weight reduction than semaglutide 2.4 mg. If you are comparing your options, the Saxenda versus Wegovy page covers another comparison that sometimes comes up alongside this one.

As of summer 2026, the MHRA has also approved an oral semaglutide tablet (Wegovy tablets) for weight management, the first oral GLP-1 medicine licensed in the UK for this purpose. It is not available on the NHS yet, and a NICE appraisal would be required before that changes.

Ozempic is not on this list. It is not licensed for weight loss. That is the regulatory position, and no amount of demand or online availability changes it.

For anyone working out where to begin, our treatment options page sets out the licensed medicines available through a regulated consultation. If cost is part of the decision, the Wegovy cost page gives an honest picture of what private treatment involves and what to look out for.

Wegovy is a prescription-only medicine. A GPhC-registered prescriber (a real clinician, not a piece of software) reviews every consultation at nume the same day it is submitted. Once approved and dispatched, the pen arrives in a plain, unbranded box via DPD with tracking sent to your phone; there is nothing on the outside to indicate what is inside. If you would like to explore whether Wegovy or Mounjaro is right for you, check your eligibility through a free consultation.